EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Reflections on adjuvant pembrolizumab for triple-negative breast cancer treated with the KEYNOTE-522 regimen: Is it really necessary?

Vitor T Liutti, Hans Wildiers, Gabe S Sonke, Patrick Neven

European Journal of Cancer · 2026-11 · 248 · 117064

DOI: 10.1016/j.ejca.2026.117064 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Cancer, 2026-11. Verfasst von Vitor T Liutti und 3 weiteren Autor:innen. Beteiligte Einrichtung: Hospital do Câncer de Londrina, Londrina, Brazil. Electronic address: vtliutti@gmail.com. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Triple Negative Breast Neoplasms, Antineoplastic Agents, Immunological. Die Arbeit nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedTriple Negative Breast NeoplasmsAntineoplastic Agents, ImmunologicalHumansFemaleChemotherapy, AdjuvantPathologic Complete ResponseRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Adjuvant therapyBreast cancerPembrolizumabTriple-negative

Substanzen

Antibodies, Monoclonal, HumanizedpembrolizumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Hospital do Câncer de Londrina, Londrina, Brazil. Electronic address: vtliutti@gmail.com.
  • Universitair Ziekenhuis Leuven, Leuven, Belgium. Electronic address: hans.wildiers@uzleuven.be.
  • Antoni van Leeuwenhoek Nederlands Kanker Instituut, Amsterdam, the Netherlands. Electronic address: g.sonke@nki.nl.
  • Universitair Ziekenhuis Leuven, Leuven, Belgium. Electronic address: patrick.neven@uzleuven.be.

Zitieren

APA

Liutti, V. T., Wildiers, H., Sonke, G. S., & Neven, P. (2026). Reflections on adjuvant pembrolizumab for triple-negative breast cancer treated with the KEYNOTE-522 regimen: Is it really necessary?. European Journal of Cancer, 248, 117064. https://doi.org/10.1016/j.ejca.2026.117064

Vancouver

Liutti VT, Wildiers H, Sonke GS, Neven P. Reflections on adjuvant pembrolizumab for triple-negative breast cancer treated with the KEYNOTE-522 regimen: Is it really necessary?. European Journal of Cancer. 2026;248:117064. doi:10.1016/j.ejca.2026.117064

BibTeX
@article{Liutti2026,
  author = {Liutti, Vitor T and Wildiers, Hans and Sonke, Gabe S and Neven, Patrick},
  title = {Reflections on adjuvant pembrolizumab for triple-negative breast cancer treated with the KEYNOTE-522 regimen: Is it really necessary?},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {248},
  pages = {117064},
  doi = {10.1016/j.ejca.2026.117064}
}
Kostenlos starten →